oncology

Holy Grail: Dr Ian Parish on repurposing drugs to expand immunotherapy-responsive killer T cells

Can thalidomide derivatives be used to selectively expand an immunotherapy-responsive population of killer T-cells? Dr Ian Parish is a senior researcher at the Peter MacCallum Cancer Centre and University of Melbourne. He recently won a $1 million Ideas Grant to explore how an existing drug could be repurposed to improve patients' responses to cancer immunotherapy.

Read more

Can you sum up the aim of your project in 10 words? To boost the efficacy of cancer immunotherapy using approved drugs. What aspect of this research excites you the most? The most exciting part of this research is that, because we’re working on repurposing drugs that are already approved, any findings that we make ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic